Intrathecal Baclofen Infusion for Ambulant Children With Cerebral Palsy

Pediatric Neurology

Volumn 40, Issue 4, 2009, Pages 265-270

  Brochard, Sylvain ^a   Remy Neris, Olivier ^a   Filipetti, Paul ^b   Bussel, Bernard ^c  

^a CHU MORVAN   (France)

^b Motion Analysis Laboratory   (France)

^c RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN;

ADOLESCENT; ADULT; ARTICLE; ASEPTIC MENINGITIS; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ENCEPHALOMENINGOCELE; FEMALE; FUNCTIONAL ASSESSMENT; GAIT; HUMAN; IMPLANTATION; LEG MUSCLE; MALE; MYOTATIC REFLEX; OUTPATIENT CARE; PHYSIOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; REIMPLANTATION; RETROSPECTIVE STUDY; SCHOOL CHILD; SKIN NECROSIS; SPASTICITY; TREATMENT DURATION; WALKING AID;

BACLOFEN; CEREBRAL PALSY; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GAIT; HUMANS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SPINAL; MALE; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; POSTURE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 62149134942     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2008.10.020     Document Type: Article

References (26)

1. SCPE Collaborative Group. Prevalence and characteristics of children with cerebral palsy in Europe. Dev Med Child Neurol 44 (2002) 633-640
2. Krigger K. Cerebral Palsy: An overview. Am Fam Physician 73 (2006) 91-102
3. Johnson D., Damiano D.L., and Abel M.F. The evolution of gait in childhood and adolescent cerebral palsy. J Pediatr Orthop 17 (1997) 392-396
4. Butler C., and Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes Committee Review Panel. Dev Med Child Neurol 42 (2000) 634-645
5. Meythaler J.M., Guin-Renfroe S., Law C., Grabb P., and Hadley M.N. Continuously infused intrathecal baclofen over 12 months for spastic hypertonia in adolescents and adults with cerebral palsy. Arch Phys Med Rehabil 82 (2001) 155-161
6. Murphy N.A., Irwin M.C., and Hoff C. Intrathecal baclofen therapy in children with cerebral palsy: Efficacy and complications. Arch Phys Med Rehabil 83 (2002) 1721-1725
7. Campbell W.M., Ferrel A., McLaughlin J.F., et al. Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol 44 (2002) 660-665
8. Gooch J.L., Oberg W.A., Grams B., Ward L.A., and Walker M.L. Care provider assessment of intrathecal baclofen in children. Dev Med Child Neurol 46 (2004) 548-552
9. Fitzgerald J.J., Tsegaye M., and Vloeberghs M.H. Treatment of childhood spasticity of cerebral origin with intrathecal baclofen: A series of 52 cases. Br J Neurosurg 18 (2004) 240-245
10. Krach L.E., Kriel R.L., Gilmartin R.C., et al. Hip status in cerebral palsy after one year of continuous intrathecal baclofen infusion. Pediatr Neurol 30 (2004) 163-168
11. Albright A.L., Barron W.B., Fasick M.P., Polinko P., and Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 270 (1993) 2475-2477
12. Van Schaeybroeck P., Nuttin B., Lagae L., Schrijvers E., Borghgraef C., and Feys P. Intrathecal baclofen for intractable cerebral spasticity: A prospective placebo-controlled, double-blind study. Neurosurgery 46 (2000) 603-612
13. Krach L.E., Kriel R.L., Gilmartin R.C., et al. GMFM 1 year after continuous intrathecal baclofen infusion. Pediatr Rehabil 8 (2005) 207-213
14. Gerszten P.C., Albright A.L., and Barry M.J. Effect on ambulation of continuous intrathecal baclofen infusion. Pediatr Neurosurg 27 (1997) 40-44
15. Bleyenheuft C., Filipetti P., Caldas C., and Lejeune T. Experience with external pump trial prior to implantation for intrathecal baclofen in ambulatory patients with spastic cerebral palsy. Clin Neurophysiol 37 (2007) 23-28
16. Palisano R., Rosenbaum P., Walter S., Russell D., Wood E., and Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 39 (1997) 214-223
17. Ashworth B. Preliminary trial of carisoprodal in multiple sclerosis. Practitioner 192 (1964) 540-542
18. Boyd R., Barwood S., Ballieu C., and Graham H. Validity of a clinical measure of spasticity in chidren with cerebral palsy in a double blind randomised controlled clinical trial. Dev Med Child Neurol 40 Suppl. 78 (1998) 7
19. Rodda J., Graham H., Carson L., Galea M., and Wolfe R. Sagittal gait patterns in spastic diplegia. J. Bone Joint Surg 86 B (2004) 251-258
20. Novacheck T., Stout J., and Tervo R. Reliability and validity of the Gillette Functional Assessment Questionnaire as an outcome measure in children with walking disabilities. J Pediatr Orthop 20 (2000) 75-79
21. Sutherland D., Kaufman K., Wyatt M., Chambers H., and Mubarak S. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 10 (1999) 1-9
22. Steinbok P. Outcomes after selective dorsal rhizotomy for spastic cerebral palsy. Childs Nerv Syst 17 (2001) 1-18
23. Sgouros S., and Seri S. The effect of intrathecal baclofen on muscle co-contraction in children with spasticity of cerebral origin. Pediatr Neurosurg 37 (2002) 225-230
24. Sakzewski L., Boyd R., and Ziviani J. Clinimetric properties of participation measures for 5- to 13-year-old children with cerebral palsy: A systematic review. Dev Med Child Neurol 49 (2007) 232-240
25. Emery E. Intrathecal baclofen. Literature review of the results and complications. Neurochirurgie 49 (2003) 276-288
26. Bottos M., Feliciangeli A., Sciuto L., Gericke C., and Vianello A. Functional status of adults with cerebral palsy and implications for treatment of children. Dev Med Child Neurol 43 (2001) 516-528